News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S (LUN.CO): Study Shows Effects of Treatment With ABILIFY MAINTENA#0153; (Aripiprazole) on Psychiatric Hospitalization Rates for Patients With Schizophrenia1


5/21/2013 10:55:14 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN FRANCISCO--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced results from a preliminary analysis that showed statistically significant reductions (p<0.0001) in total psychiatric hospitalization rates in patients diagnosed with schizophrenia who were converted to once-monthly ABILIFY MAINTENA™ (aripiprazole) – an extended-release injectable suspension formulation of aripiprazole – compared to previous treatment with daily standard-of-care (SOC) oral antipsychotics.1 Relapse, or an acute exacerbation of the disease, can result in hospitalization.2 It also has been reported that hospitalization may contribute to higher health care costs.3 These data were presented in a poster at the 166th American Psychiatric Association (APA) Annual Meeting in San Francisco on May 21.1

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES